A novel small molecule inhibitor of FAK and IGF-1R protein interactions decreases growth of human esophageal carcinoma

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 7, 2011, Pages 629-637

  Ucar, Deniz A ^a   Cox, Audrey ^a   He, Di Hua ^a   Ostrov, David A ^a   Kurenova, Elena ^b   Hochwald, Steven N ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cancer; Cell survival; Esophageal cancer; Esophagus; FAK; IGF 1R

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOCAL ADHESION KINASE; INT 2 31; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NSC 344553; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL VIABILITY; DOSE RESPONSE; DRUG STRUCTURE; ENZYME INHIBITION; ESOPHAGUS CARCINOMA; FEMALE; HIGH THROUGHPUT SCREENING; MOLECULAR DOCKING; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 80051754822     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011796817718     Document Type: Article

References (30)

1. American Cancer Society: Cancer Facts and Figures 2009. Atlanta, Ga: American Cancer Society, 2009.
2. Eloubeidi, M.A.; Mason, A.C.; Desmond, R.A.; El-Serag, H.B. Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am. J. Gastroenterol., 2003, 98(7), 1627-1633.
3. Allum, W.H.; Stenning, S.P.; Bancewicz, J.; Clark, P.I.; Langley, R.E. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J. Clin. Oncol., 2009, 27(30), 5062-5067.
4. Juergens, R.A.; Forastiere, A. Combined modality therapy of esophageal cancer. J. Natl. Compr. Canc. Netw., 2008, 6(9), 851-861.
5. Burridge, K.; Turner, C.E.; Romer, L.H. Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: a role in cytoskeletal assembly. J. Cell. Biol., 1992, 119(4), 893-903.
6. Cary, L.A.; Guan, J.L. Focal adhesion kinase in integrin-mediated signaling. Front Biosci., 1999, 4, D102-D113.
7. Guan, J.L.; Shalloway, D. Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature, 1992, 358(6388), 690-692.
8. Kornberg, L.J.; Earp, H.S.; Turner, C.E.; Prockop, C.; Juliano, R.L. Signal transduction by integrins: increased protein tyrosine phosphorylation caused by clustering of beta 1 integrins. Proc. Natl. Acad. Sci. USA, 1991, 88(19), 8392-8396.
9. Watanabe, N.; Takaoka, M.; Sakurama, K.; Tomono, Y.; Hatakeyama, S.; Ohmori, O.; Motoki, T.; Shirakawa, Y.; Yamatsuji, T.; Haisa, M.; Matsuoka, J.; Beer, D.G.; Nagatsuka, H.; Tanaka, N.; Naomoto, Y. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-1 receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo. Clin. Cancer Res., 2008, 14(14), 4631-4639.
10. Ouban, A.; Muraca, P.; Yeatman, T.; Coppola, D. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum. Pathol., 2003, 34(8), 803-808.
11. Liu, Y.C.; Leu, C.M.; Wong, F.H.; Fong, W.S.; Chen, S.C.; Chang, C.; Hu, C.P. Autocrine stimulation by insulin-like growth factor I is involved in the growth, tumorigenicity and chemoresistance of human esophageal carcinoma cells. J. Biomed. Sci., 2002, 9(6 Pt 2), 665-674.
12. Kalinina, T.; Bockhorn, M.; Kaifim, J.T.; Thieltges, S.; Güngör, C.; Effenberger, K.E.; Strelow, A.; Reichelt, U.; Sauter, G.; Pantel, K.; Izbicki, J.R.; Yekebas, E.F. Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a Co-Target in the treatment of human adenocarcinoma of the esophagus. Int. J. Cancer, 2010, 127(8), 1931-1940.
13. Piao, W.; Wang, Y.; Adachi, Y.; Yamamoto, H.; Li, R.; Imsumran, A.; Li, H.; Maehata, T.; Ii, M.; Arimura, Y.; Lee, C.T.; Shinomura, Y.; Carbone, D.P.; Imai, K. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas. Mol. Cancer Ther., 2008, 7(6), 1483-1493.
14. Kusayama, M.; Wada, K.; Nagata, M.; Ishimoto, S.; Takahashi, H.; Yoneda, M.; Nakajima, A.; Okura, M.; Kogo, M.; Kamisaki, Y. Critical role of aquaporin 3 on growth of human esophageal and oral squamous cell carcinoma. Cancer Sci., 2011, 102(6), 1128-1136.
15. Piao, W.; Wang, Y.; Adachi, Y.; Yamamoto, H.; Li, R.; Imsumran, A.; Li, H.; Maehata, T.; Ii, M.; Arimura, Y.; Lee, C.T.; Shinomura, Y.; Carbone, D.P.; Imai, K. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas. Mol. Cancer Ther., 2008, 7(6), 1483-1493.
16. Liu, W.; Bloom, D.A.; Cance, W.G.; Golubovskaya, V.; Kurenova, E.; Hochwald, S.N. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis, 2008, 29(6), 1096-1107.
17. Hochwald, S.N.; Nyberg, C.; Zheng, M.; Wood, C.; Massoll, N.A.; Magis, A.; Ostrov, D.; Cance, W.G.; Golubovskaya, V.M. A novel small molecule inhibitor of FAK autophosphorylation decreases growth of human pancreatic cancer. Cell Cycle, 2009, 8(15), 2435-2443.
18. Zheng, D.; Golubovskaya, V.; Kurenova, E.; Beierle, E.; Wood, C.; Massoll, N.A.; Ostrov, D.; Cance, W.G.; Hochwald, S.N. A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts. Mol. Carcinog., 2010, 49(2), 200-209.
19. Zheng, D.; Kurenova, E.; Ucar, D.; Golubovskaya, V.; Magis, A.; Ostrov, D.; Cance, W.G.; Hochwald, S.N. Targeting of the protein interaction site between FAK and IGF-1R. Biochem. Biophys. Res. Comm., 2009, 388(2), 301-305.
20. Golubovskaya, V.M.; Nyberg, C.; Zheng, M.; Kweh, F.; Magis, A.; Ostrov, D.; Cance, W.G. A Small Molecule Inhibitor, 1,2,4,5-Benzenetetraamine Tetrahydrochloride, Targeting the Y397 Site of Focal Adhesion Kinase Decreases Tumor Growth. J. Med. Chem., 2008, 51(23), 7405-7416.
21. Kurenova, E.V.; Hunt, D.L.; He, D.; Magis, A.T.; Ostrov, D.A.; Cance, W.G. Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo. J. Med. Chem., 2009, 52(15), 4716-4724.
22. Ceccarelli, D.F.; Song, H.K.; Poy, F.; Schaller, M.D.; Eck, M.J. Crystal structure of the FERM domain of focal adhesion kinase. J. Biol. Chem., 2006, 281(1), 252-259.
23. Munshi, S.; Kornienko, M.; Hall, D.L.; Reid, J.C.; Waxman, L.; Stirdivant, S.M.; Darke, P.L.; Kuo, L.C. Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase. Implication for inhibitor specificity. J. Biol. Chem., 2002, 277(41), 38797-38802.
24. Ucar, D.; Kurenova, E.; Cance, W.G.; Ostrov, D.A.; Lawrence, N.; Sebit, S.; Hochwald, S.N. A novel small molecule inhibitor disrupts protein interactions of FAK and IGF-1R and inhibits melanoma tumor growth. In press, Carcinogenesis.
25. Ku, G.Y.; Ilson, D.H. Esophagogastric cancer: targeted agents. Cancer Treat. Rev., 2010, 36(3), 235-248.
26. Hochwald, S.N.; Golubovskaya, G.V. FAK as a target for cancer therapy. Gene Ther. Mol. Biol., 2010, 13(1),26-35.
27. Pollak, M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer, 2009, 8(12), 915-928.
28. Chappell, W.H.; Steelman, L.S.; Long, J.M.; Kempf, R.C.; Abrams, S.L.; Franklin, R.A.; Bäsecke, J.; Stivala, F.; Donia, M.; Fagone, P.; Malaponte, G.; Mazzarino, M.C.; Nicoletti, F.; Libra, M.; Maksimovic-Ivanic, D.; Mijatovic, S.; Montalto, G.; Cervello, M.; Laidler, P.; Milella, M.; Tafuri, A.; Bonati, A.; Evangelisti, C.; Cocco, L.; Martelli, A.M.; McCubrey, J.A. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. Oncotarget., 2011, 2(3), 135-164.
29. Roberts, W.G.; Ung, E.; Whalen, P.; Cooper, B.; Hulford, C.; Autry, C.; Richter, D.; Emerson, E.; Lin, J.; Kath, J.; Coleman, K.; Yao, L.; Martinez-Alsina, L.; Lorenzen, M.; Berliner, M.; Luzzio, M.; Patel, N.; Schmitt, E.; LaGreca, S.; Jani, J.; Wessel, M.; Marr, E.; Griffor, M.; Vajdos, F. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res., 2008, 68(6), 1935-1944.
30. Andersson, S.; D'Arcy, P.; Larsson, O.; Sehat, B. Focal adhesion kinase (FAK) activates and stabilizes IGF-1 receptor. Biochem. Biophys. Res. Commun., 2009, 387(1), 36-41.